Cardiovascular Effects of COVID-19
NCT04365699
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
81
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
Interventions
DRUG:
AT-001
Sponsor
NYU Langone Health